380550.KQ NEUROPHET, Inc.
- Market cap
- KRW 68.4B
- P/E
- -
- P/B
- 1.98x
- ROE
- -64.6%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 380550.KQ undervalued?
Graham numberThe Graham number of NEUROPHET, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NEUROPHET, Inc. fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-64.6%), below 10%.
ROA 1/1
Return on assets (-45.5%) is above the industry median (-82.9%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-40.7%) is below the industry median (-16.0%).
Revenue Growth 2/2
Revenue grew 59.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (17.6%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Cash Runway 0/2
Cash covers 0.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (2.0x) is above the industry median (1.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
NEUROPHET, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NEUROPHET, Inc.
NEUROPHET, Inc., operates as a neuroscience company, engages in the development of medical artificial intelligence solutions in the field of brain science and diseases. The company offers Neurophet AQUA, AI-powered diagnosis assistant software for brain diseases; Neurophet SCALE PET, a software that quantitatively analyzes biomarkers targeted by a specific radiotracer using PET; Neurophet tES LAB, AI-Powered software to generate a 3D model using brain MRI and simulate electr…
Full company profileNEUROPHET, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NEUROPHET, Inc. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 647M | 1.56B | 2.22B | 2.62B | 2.53B |
| Gross Profit | 664M | 1.43B | 2.22B | 2.62B | 2.52B |
| Operating Income | -9.42B | -11.8B | -14.6B | -16.5B | -22.1B |
| EBITDA | -15.5B | 8.58B | -10.4B | -20.4B | -22.2B |
| Net Income | -18.3B | 5.26B | -15.1B | -22.4B | -22.8B |
| EPS | -1,597 | 459 | -1,316 | -1,852 | -1,886 |
| Balance Sheet | |||||
| Total Assets | 13.3B | 23.1B | 9.86B | 26.9B | 50.1B |
| Total Liabilities | 57.0B | 59.8B | 61.1B | 7.43B | 14.8B |
| Shareholders' Equity | -43.7B | -36.6B | -51.2B | 19.5B | 35.3B |
| Cash & Short-term Investments | 1.82B | 6.67B | 3.02B | 4.10B | 3.80B |
| Cash Flow | |||||
| Operating Cash Flow | -7.29B | -8.97B | -12.6B | -15.1B | -19.6B |
| Capital Expenditure | 364M | 313M | 393M | 325M | 924M |
| Free Cash Flow | -7.66B | -9.29B | -13.0B | -15.4B | -20.5B |
| Ratios | |||||
| ROE | - | - | - | -115.1% | -64.6% |
| ROA | -138.1% | 22.7% | -153.2% | -83.3% | -45.5% |
| Net Profit Margin | -2,831.1% | 336.9% | -681.4% | -856.2% | -902.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NEUROPHET, Inc. dividends
NEUROPHET, Inc. has not paid dividends in the last 4 fiscal years.
Who owns NEUROPHET, Inc.
- Insiders 25.20%
- Institutions 3.08%
- Public & others 71.73%
- Shares outstanding 12.2M
- Free float 6.83M
NEUROPHET, Inc. company profile
- Company name
- NEUROPHET, Inc.
- Ticker
- 380550.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Health Information Services
- Employees
- 144
- Fiscal year end
- December
- Address
- Samwon Tower, Seoul, South Korea
- Phone
- 82 2 6954 7971
- Website
- neurophet.com
About NEUROPHET, Inc.
NEUROPHET, Inc., operates as a neuroscience company, engages in the development of medical artificial intelligence solutions in the field of brain science and diseases. The company offers Neurophet AQUA, AI-powered diagnosis assistant software for brain diseases; Neurophet SCALE PET, a software that quantitatively analyzes biomarkers targeted by a specific radiotracer using PET; Neurophet tES LAB, AI-Powered software to generate a 3D model using brain MRI and simulate electrical stimulation for treatment planning; and Neurophet innk, a non-invasive electrical stimulation device designed to aid in the functional recovery and rehabilitation of patients with brain diseases. It also provides Consulting services for design systems and quality management systems. The company has a strategic collaboration with VHIR Vall d'Hebron Institut de Recerca for the development of AI algorithms that detect multiple sclerosis lesions using MRI data. The company was founded in 2016 and is headquartered in Seoul, South Korea.
NEUROPHET, Inc. management
9- Mr. Junkil BeenCo-CEO & Chairman · born 1988
- Mr. Dong Hyeon KimCO-CEO, CTO, Head of R&D and Director · born 1987
- Mr. Kwang Min LeeCFO, Head of Management & Director · born 1978
- Mr. Sang Jun KimDirector of IR & PR
- Ms. Ji-Young LeeDirector of HR
- Mr. ChangIl KimCPO, Head of Product & Director · born 1969
- Mr. Hyun Kook LimCMO & Director · born 1972
- Mr. Young Joon MoonCBO, Head of Business & Director · born 1976
- Mr. Josh CohenHead of Americas Business